201
|
Skariah S, Walwyn O, Engelberg K, Gubbels MJ, Gaylets C, Kim N, Lynch B, Sultan A, Mordue DG. The FIKK kinase of Toxoplasma gondii is not essential for the parasite's lytic cycle. Int J Parasitol 2016; 46:323-32. [PMID: 26859096 DOI: 10.1016/j.ijpara.2016.01.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2015] [Revised: 01/05/2016] [Accepted: 01/07/2016] [Indexed: 10/22/2022]
Abstract
FIKK kinases are a novel family of kinases unique to the Apicomplexa. While most apicomplexans encode a single FIKK kinase, Plasmodium falciparum expresses 21 and piroplasms do not encode a FIKK kinase. FIKK kinases share a conserved C-terminal catalytic domain, but the N-terminal region is highly variable and contains no known functional domains. To date, FIKK kinases have been primarily studied in P. falciparum and Plasmodium berghei. Those that have been studied are exported from the parasite and associate with diverse locations in the infected erythrocyte cytosol or membrane. Deletion of individual P. falciparum FIKK kinases indicates that they may play a role in modification of the infected erythrocyte. The current study characterises the single FIKK gene in Toxoplasma gondii to evaluate the importance of the FIKK kinase in an apicomplexan that has a single FIKK kinase. The TgFIKK gene encoded a protein of approximately 280kDa. Endogenous tagging of the FIKK protein with Yellow Fluorescent Protein showed that the FIKK protein exclusively localised to the posterior end of tachyzoites. A Yellow Fluorescent Protein-tagged FIKK and a Ty-tagged FIKK both co-localised with T. gondii membrane occupation and recognition nexus protein to the basal complex and were localised apical to inner membrane complex protein-5 and Centrin2. Deletion of TgFIKK, surprisingly, had no detectable effect on the parasite's lytic cycle in vitro in human fibroblast cells or in acute virulence in vivo. Thus, our results clearly show that while the FIKK kinase is expressed in tachyzoites, it is not essential for the lytic cycle of T. gondii.
Collapse
|
202
|
Lee C, Yang H, Kim S, Kim M, Kang H, Kim N, An S, Koh J, Jung H. Evaluation of the anti-wrinkle effect of an ascorbic acid-loaded dissolving microneedle patch via a double-blind, placebo-controlled clinical study. Int J Cosmet Sci 2016; 38:375-81. [PMID: 26648582 DOI: 10.1111/ics.12299] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2015] [Accepted: 11/29/2015] [Indexed: 12/31/2022]
Abstract
OBJECTIVE Although an ascorbic acid-loaded dissolving microneedle patch has been developed to improve anti-wrinkle effects, an efficacy evaluation with a control group has not yet been performed. In this study, the anti-wrinkle effect of an ascorbic acid-loaded dissolving microneedle patch was evaluated in a double-blind clinical study with a control group. In addition, a cumulative skin irritation and sensitization potential of the ascorbic acid-loaded dissolving microneedle patch was performed. METHODS Twenty-three subjects were selected for anti-wrinkle effect evaluation in a double-blind clinical study. Subjects were divided into two groups. Group I subjects applied an ascorbic acid-loaded dissolving microneedle patch on a crow's feet area on the left side of the face and a control sample on a crow's feet area on the right side of the face every 4 days. Group II subjects placed the same patches on opposite sides of the face. Global Photodamage Score and skin replica analysis were conducted by visual inspection and skin visiometer, respectively. A skin irritation and sensitization assessment was performed on 51 subjects using the modified Shelanski & Shelanski procedure. Cumulative skin irritation potential and skin sensitization of the ascorbic acid-loaded dissolving microneedle patch and control sample were evaluated. RESULTS Skin treated with the ascorbic acid-loaded dissolving microneedle patch showed a statistically significant improvement in both the Global Photodamage Score and visiometer R values (P < 0.05) compared with the control sample. The R2 value (maximum roughness), in particular, showed a highly significant improvement (P < 0.01). The skin irritation and sensitization assessment demonstrated that the ascorbic acid-loaded dissolving microneedle patch did not induce any cumulative skin irritation potential or skin sensitization. CONCLUSIONS An ascorbic acid-loaded dissolving microneedle patch produced a significant anti-wrinkle effect without skin irritation and sensitization problems. This cosmetic dissolving microneedle patch can be used efficiently in the anti-wrinkle cosmetic field with patient convenience.
Collapse
|
203
|
Jeong J, Kim N, Kim T, Lim H, Hong S, Han J. Sleep and cognitive problems in patients with attention-deficit hyperactivity disorder. Sleep Med 2015. [DOI: 10.1016/j.sleep.2015.02.1417] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
204
|
Kim N, Lee W. Adjunctive photodynamic therapy for type 1 choroidal neovascularization associated with thickened choroid. Acta Ophthalmol 2015. [DOI: 10.1111/j.1755-3768.2015.0545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
205
|
Song GW, Ahn CS, Lee SG, Hwang S, Kim KH, Moon DB, Ha TY, Jung DH, Park GC, Kang SH, Jung BH, Kim N. Correlation between risk of hepatitis B virus recurrence and tissue expression of covalently closed circular DNA in living donor liver transplant recipients treated with high-dose hepatitis B immunoglobulin. Transplant Proc 2015; 46:3548-53. [PMID: 25498087 DOI: 10.1016/j.transproceed.2014.06.074] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2014] [Revised: 05/05/2014] [Accepted: 06/17/2014] [Indexed: 01/16/2023]
Abstract
BACKGROUND AND AIMS Despite the application of prophylaxis, the risk of hepatitis B virus (HBV) recurrence remains. However, actual mechanism(s) and definite risk factor(s) are obscure. The present study examined the correlation between the HBV load in liver explants and post-liver transplant (OLT) HBV recurrence. METHODS HBV DNA was extracted from liver tissue taken from 50 living donor OLT (LDLT) patients using the QuickGene DNA Tissue Kit S (Fujifilm, Tokyo, Japan) and subjected to real-time polymerase chain reaction with the following primers: 5'-CACATGGCCTCCAAGGAGTAA-3' (forward primer) and 5'-TGAGGGTCTCTCTCTTCCTCTTGT-3' (reverse primer). To prevent HBV infection, patients were treated daily with high-dose (10,000 IU) hepatitis B immunoglobulin (HBIG) for the first week after LDLT. They then received weekly doses for the next month and then monthly doses for ≤1 year. If the anti-hepatitis surface antigen antibody titer was <1,000 IU/L, an antiviral agent (AVA) was added to the regimen. RESULTS The mean (±SD) tissue HBV DNA and covalently closed circular DNA (cccDNA) loads were -0.8 ± 1.2 (range, -2.9 to 2.6) and -2.3 ± 1.1 (range, -4.6 to 0.6) log10 copies/cell, respectively. There was a significant correlation between serum and tissue HBV DNA (r = 0.65; P = .00) and cccDNA concentrations (r = 0.55; P = .00). Six patients suffered HBV recurrence and 9 required additional AVA. There was no direct correlation between HBV recurrence and tissue cccDNA concentration. However, the concentration of cccDNA was significantly greater those patients suffering recurrence and receiving AVA treatment (high-risk group). CONCLUSION High tissue cccDNA concentrations may be a risk factor for HBV recurrence despite high-dose HBIG prophylaxis.
Collapse
|
206
|
Lee S, Kim Y, Kim N. Novel echocardiographic parameter for prediction of cardioembolic stroke. Atherosclerosis 2015. [DOI: 10.1016/j.atherosclerosis.2015.04.769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
207
|
Kim N, Kwak SH, Lee SH, Juvekar V, Lee BI, Ahn HC, Kim SY, Gong YD. Novel 3-arylethynyl-substituted thieno[3,4-b]pyrazine derivatives as human transglutaminase 2 inhibitors. Org Biomol Chem 2015; 12:4932-40. [PMID: 24879506 DOI: 10.1039/c4ob00179f] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
In the process of optimization, we developed a novel core skeleton of thieno[3,4-b]pyrazine via GK-13. The derivatives synthesized were shown to inhibit TGase 2 activity in cancer cells. Some of the hit compounds such as the arylethynyl group-coupled thieno[3,4-b]pyrazine derivatives were shown to exhibit promising activity for use as potential therapeutic small-molecules in renal cancer by inhibiting TGase 2 activity.
Collapse
|
208
|
Park YW, Kee SJ, Kim N, Jin HM, Cho YN, Lee SJ, Lee JW, Lee KE, Yim YR. THU0045 Dysregulated Osteoclastogenesis is Related to Natural Killer T Cell Dysfunction in Rheumatoid Arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
209
|
Hong J, Sung S, Hasan A, Jung M, Eun J, Kim N, Nam E, Kang Y. AB0123 Real-Time in Vivo Apoptosis Imaging with a Histone-H1 Targeting Probe for the Measurement of therapeutic Response in an Experimental Arthritis Model. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
210
|
Boehncke WH, Qureshi A, Merola JF, Thaçi D, Krueger GG, Walsh J, Kim N, Gottlieb AB. Diagnosing and treating psoriatic arthritis: an update. Br J Dermatol 2015; 170:772-86. [PMID: 24266754 DOI: 10.1111/bjd.12748] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/18/2013] [Indexed: 12/14/2022]
Abstract
Psoriatic arthritis (PsA) is an inflammatory arthritis of uncertain pathogenesis, affecting approximately one in four patients with psoriasis. Onset of psoriasis typically precedes the development of PsA. Therefore, the dermatologist is ideally positioned to recognize the early signs and symptoms of PsA for diagnosis and subsequent treatment. The role of the dermatologist in early diagnosis and treatment is essential for preventing pain and functional disabilities, as well as the joint deterioration that accompanies progressive forms of PsA. Diagnosis of PsA is a key aspect of the clinical decision process for the dermatologist, as psoriasis plus PsA requires a different therapeutic approach from that required for psoriasis alone. Furthermore, PsA is associated with an increased risk of cardiovascular comorbidities that present significant health concerns. In this review, the pathogenesis and comorbidities of PsA are discussed. In addition, screening and imaging tools that aid in the diagnosis of PsA, as well as tools used for efficacy assessment, are reviewed. Available therapies are presented, with a focus on targeted biologics and emerging treatments.
Collapse
|
211
|
Kim N, Shin Y, Choi S, Namkoong E, Kim M, Lee J, Song Y, Park K. Effect of Antimuscarinic Autoantibodies in Primary Sjögren's Syndrome. J Dent Res 2015; 94:722-8. [PMID: 25784251 DOI: 10.1177/0022034515577813] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
The presence of functional autoantibodies against the muscarinic type 3 receptor (M3R) has been reported in primary Sjögren's syndrome (pSS). However, the pathogenic role of these autoantibodies in pSS development remains to be elucidated. In this experiment, we investigated a pathologic role of pSS autoantibodies (pSS IgG) associated with downregulation of the major histocompatibility complex I (MHC I) molecule with M3R through internalization. Anti-M3R autoantibodies in purified control and pSS IgG were detected using 4 synthesized cyclic M3R peptides by enzyme-linked immunosorbent assay. The binding reactivity of pSS IgG to M3R in situ was analyzed by a dual immunostaining method. Surface expression, interaction, and internalization of M3R with MHC I were analyzed by immunofluorescence confocal microscopy and biochemical assays. Synthetic cyclic peptides M3RP(205-221) and M3RP(520-527) showed significantly high reactivity with pSS IgG compared to the control IgG or the other 3 peptides (P < 0.05). Significantly high reactivity of pSS IgG to M3R in situ was observed. PSS IgG increased the interaction of membrane M3R with MHC I and induced their internalization in primary human submandibular gland cells. The pSS IgG-induced internalization of M3R with MHC I was significantly inhibited by the cholesterol-sequestering drug filipin. Our novel finding-namely, strong downregulation of the membrane MHC I with M3R through internalization of the cholesterol-rich microdomain associating with anti-M3R autoantibodies-could be an important mechanism contributing to the impaired salivation seen in pSS and linking secretory hypofunction to autoimmune pathogenesis.
Collapse
|
212
|
Ko HS, Kim N, Park YG. Re: Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome. BJOG 2015; 122:585. [DOI: 10.1111/1471-0528.13067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/15/2014] [Indexed: 11/30/2022]
|
213
|
Ha TY, Hwang S, Kim KH, Lee YJ, Ahn CS, Moon DB, Song GW, Park KM, Kim N, Lee SG. Expression pattern analysis of hepatocellular carcinoma tumor markers in viral hepatitis B and C patients undergoing liver transplantation and resection. Transplant Proc 2015; 46:888-93. [PMID: 24767373 DOI: 10.1016/j.transproceed.2013.12.037] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2013] [Revised: 11/30/2013] [Accepted: 12/11/2013] [Indexed: 12/15/2022]
Abstract
BACKGROUND This study was conducted to compare the expression patterns of serum alpha-fetoprotein (AFP) and proteins induced by vitamin K absence or antagonist-II (PIVKA-II) in hepatocellular carcinoma (HCC) patients undergoing liver transplantation (LT) and resection at a high-volume single institution. METHODS First, 663 liver transplant recipients with HCC were selected. They were divided into hepatitis B virus (HBV) (n = 628) and hepatitis C virus (HCV) groups (n = 35). Their medical records were retrospectively reviewed. Second, another cohort of 2709 patients who underwent HCC resection included 2258 HBV, 143 HCV, and 308 non-HBV non-HCV (NBNC) patients. RESULTS In the transplantation group, pretransplantation AFP level >20 ng/mL was observed in 42.5% of HBV patients and 60% of HCV patients (P = .042). PIVKA-II level >40 mAU/mL was observed in 30.6% of HBV patients and 42.9% of HCV patients (P = .127). In the resection group, a preoperative AFP level >20 ng/mL was observed in 51.7% of HBV patients and 43.3% of HCV patients (P = .052). PIVKA-II level >40 mAU/mL was observed in 59.7% of HBV patients and 56.6% of HCV patients (P = .47). Preoperative AFP level >20 ng/mL and PIVKA-II level >40 mAU/mL were observed in 35.7% and 61% of NBNC patients, respectively. Receiver-operator characteristic curve analyses revealed that the expression pattern of PIVKA-II in patients with elevated AFP level was not predictable and vice versa, regardless of background liver diseases. CONCLUSIONS This study indicates that serum AFP and PIVKA-II may be expressed variably regardless of the types of background liver disease. Further large-volume multicenter studies are needed to evaluate the possibility of the etiology-dependent expression of tumor markers.
Collapse
|
214
|
Park YH, Hwang S, Song GW, Jung DH, Ahn CS, Kim KH, Moon DB, Ha TY, Park GC, Kim N, Lee SG. Correlation between mycophenolic acid blood level and renal dysfunction in stable liver transplant recipients receiving mycophenolate monotherapy. Transplant Proc 2015; 46:811-5. [PMID: 24767354 DOI: 10.1016/j.transproceed.2013.12.042] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2013] [Revised: 11/30/2013] [Accepted: 12/11/2013] [Indexed: 10/25/2022]
Abstract
PURPOSE Mycophenolate mofetil (MMF) is frequently used after liver transplantation (OLT). Mycophenolic acid (MPA) metabolites are eliminated primarily via the kidneys. If renal function declines, clearance is significantly impaired. The aim of this study was to reveal the renal function-dependent changes of MPA level in stable adult OLT recipients receiving MMF monotherapy. METHODS Sixty-five OLT recipients were selected from our OLT database of >3500 cases. All had undergone MMF monotherapy with a daily MMF dose of 1000 mg or 1500 mg for more than 2 years, primarily because they could not tolerate calcineurin inhibitors. Their clinical profiles, including MPA therapeutic drug monitoring (TDM) and renal function, were analyzed as a cross-sectional study. RESULTS For the group treated with 1000 mg MMF (n = 40), the 12-hour MPA trough level was 1.20 ± 0.35 μg/mL with serum creatinine (Cr) level ≤1.4 mg/dL in 13 patients; it was 2.78 ± 1.19 μg/mL with Cr >1.4 mg/dL in 16 patients not undergoing hemodialysis and 3.83 ± 0.87 μg/mL in 11 patients undergoing hemodialysis (P < .001). For the group treated with 1500 mg MMF (n = 25), the MPA trough level was 2.23 ± 0.99 μg/mL with Cr ≤1.4 mg/dL in 6 patients; it was 2.81 ± 0.99 μg/mL with Cr >1.4 mg/dL in 18 patients not undergoing hemodialysis and 3.5 μg/mL in 1 patient undergoing hemodialysis (P = .21). CONCLUSIONS Considering the potential therapeutic range of MPA, the suggested MMF dosage for Korean adult OLT recipients requiring hemodialysis may be set around 1000 mg per day. We suggest adjusting the MMF dosage on an individualized basis according to the results of MPA TDM, particularly for patients with markedly impaired renal function.
Collapse
|
215
|
Ko HS, Kim N, Park YG. Re: interobserver agreement in describing adnexal masses using the International Ovarian Tumor Analysis simple rules in a real-time setting and using three-dimensional ultrasound volumes and digital clips. ULTRASOUND IN OBSTETRICS & GYNECOLOGY : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF ULTRASOUND IN OBSTETRICS AND GYNECOLOGY 2015; 45:238. [PMID: 25627099 DOI: 10.1002/uog.14716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/23/2014] [Accepted: 10/27/2014] [Indexed: 06/04/2023]
|
216
|
Chung CY, Park YL, Kim N, Oh HH, Myung DS, Kim JS, Cho SB, Lee WS, Kim HS, Ahn BW, Joo YE. Rice prolamin extract ameliorates acute murine colitis by inhibiting nuclear factor-kappa B and modulating intestinal apoptosis and cell proliferation. Clin Exp Immunol 2015; 178:537-47. [PMID: 25098704 DOI: 10.1111/cei.12431] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/02/2014] [Indexed: 12/19/2022] Open
Abstract
We investigated the impact of rice prolamin extract (RPE) on lipopolysaccharide (LPS)-induced nuclear factor (NF)-κB signalling in intestinal epithelial cells and macrophages, and determined the therapeutic efficacy of RPE in acute murine colitis. The effect of RPE on LPS-induced NF-κB signalling and proinflammatory gene expression was evaluated by reverse transcription-polymerase chain reaction (RT-PCR), Western blotting, immunofluorescence and electrophoretic mobility shift assay (EMSA). The in-vivo efficacy of RPE was assessed in mice with 3% dextran sulphate sodium (DSS)-induced colitis. Apoptotic and cellular proliferative activities were evaluated by immunostaining with cleaved caspase-3 and proliferating cell nuclear antigen (PCNA) antibodies. RPE inhibited LPS-induced expression of monocyte chemotactic protein (MCP)-1, interleukin (IL)-6 and tumour necrosis factor (TNF)-alpha and LPS-induced NF-κB signalling in intestinal epithelial cells and macrophages. RPE-fed, DSS-exposed mice showed less weight loss, longer colon length and lower histological score compared to control diet-fed, DSS-exposed mice. Immunostaining analysis revealed a significant decrease of cleaved caspase-3 positive cells in RPE-fed, DSS-exposed mice compared to DSS-exposed mice. Also, the number of PCNA-positive cells within intact colonic crypts decreased significantly in RPE-fed, DSS-exposed mice compared to control diet-fed, DSS-exposed mice. DSS-induced NF-κB signalling was inhibited by RPE. RPE ameliorates intestinal inflammation by inhibiting NF-κB activation and modulating intestinal apoptosis and cell proliferation in an acute murine colitis.
Collapse
|
217
|
Aasi J, Abbott BP, Abbott R, Abbott T, Abernathy MR, Accadia T, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Affeldt C, Agathos M, Aggarwal N, Aguiar OD, Ain A, Ajith P, Alemic A, Allen B, Allocca A, Amariutei D, Andersen M, Anderson R, Anderson SB, Anderson WG, Arai K, Araya MC, Arceneaux C, Areeda J, Aston SM, Astone P, Aufmuth P, Aulbert C, Austin L, Aylott BE, Babak S, Baker PT, Ballardin G, Ballmer SW, Barayoga JC, Barbet M, Barish BC, Barker D, Barone F, Barr B, Barsotti L, Barsuglia M, Barton MA, Bartos I, Bassiri R, Basti A, Batch JC, Bauchrowitz J, Bauer TS, Behnke B, Bejger M, Beker MG, Belczynski C, Bell AS, Bell C, Bergmann G, Bersanetti D, Bertolini A, Betzwieser J, Beyersdorf PT, Bilenko IA, Billingsley G, Birch J, Biscans S, Bitossi M, Bizouard MA, Black E, Blackburn JK, Blackburn L, Blair D, Bloemen S, Blom M, Bock O, Bodiya TP, Boer M, Bogaert G, Bogan C, Bond C, Bondu F, Bonelli L, Bonnand R, Bork R, Born M, Boschi V, Bose S, Bosi L, Bradaschia C, Brady PR, Braginsky VB, Branchesi M, Brau JE, Briant T, Bridges DO, Brillet A, Brinkmann M, Brisson V, Brooks AF, Brown DA, Brown DD, Brückner F, Buchman S, Bulik T, Bulten HJ, Buonanno A, Burman R, Buskulic D, Buy C, Cadonati L, Cagnoli G, Bustillo JC, Calloni E, Camp JB, Campsie P, Cannon KC, Canuel B, Cao J, Capano CD, Carbognani F, Carbone L, Caride S, Castiglia A, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Celerier C, Cella G, Cepeda C, Cesarini E, Chakraborty R, Chalermsongsak T, Chamberlin SJ, Chao S, Charlton P, Chassande-Mottin E, Chen X, Chen Y, Chincarini A, Chiummo A, Cho HS, Chow J, Christensen N, Chu Q, Chua SSY, Chung S, Ciani G, Clara F, Clark JA, Cleva F, Coccia E, Cohadon PF, Colla A, Collette C, Colombini M, Cominsky L, Constancio M, Conte A, Cook D, Corbitt TR, Cordier M, Cornish N, Corpuz A, Corsi A, Costa CA, Coughlin MW, Coughlin S, Coulon JP, Countryman S, Couvares P, Coward DM, Cowart M, Coyne DC, Coyne R, Craig K, Creighton JDE, Crowder SG, Cumming A, Cunningham L, Cuoco E, Dahl K, Canton TD, Damjanic M, Danilishin SL, D'Antonio S, Danzmann K, Dattilo V, Daveloza H, Davier M, Davies GS, Daw EJ, Day R, Dayanga T, Debreczeni G, Degallaix J, Deléglise S, Del Pozzo W, Denker T, Dent T, Dereli H, Dergachev V, De Rosa R, DeRosa RT, DeSalvo R, Dhurandhar S, Díaz M, Di Fiore L, Di Lieto A, Di Palma I, Di Virgilio A, Donath A, Donovan F, Dooley KL, Doravari S, Dossa S, Douglas R, Downes TP, Drago M, Drever RWP, Driggers JC, Du Z, Dwyer S, Eberle T, Edo T, Edwards M, Effler A, Eggenstein H, Ehrens P, Eichholz J, Eikenberry SS, Endrőczi G, Essick R, Etzel T, Evans M, Evans T, Factourovich M, Fafone V, Fairhurst S, Fang Q, Farinon S, Farr B, Farr WM, Favata M, Fehrmann H, Fejer MM, Feldbaum D, Feroz F, Ferrante I, Ferrini F, Fidecaro F, Finn LS, Fiori I, Fisher RP, Flaminio R, Fournier JD, Franco S, Frasca S, Frasconi F, Frede M, Frei Z, Freise A, Frey R, Fricke TT, Fritschel P, Frolov VV, Fulda P, Fyffe M, Gair J, Gammaitoni L, Gaonkar S, Garufi F, Gehrels N, Gemme G, Genin E, Gennai A, Ghosh S, Giaime JA, Giardina KD, Giazotto A, Gill C, Gleason J, Goetz E, Goetz R, Gondan L, González G, Gordon N, Gorodetsky ML, Gossan S, Gossler S, Gouaty R, Gräf C, Graff PB, Granata M, Grant A, Gras S, Gray C, Greenhalgh RJS, Gretarsson AM, Groot P, Grote H, Grover K, Grunewald S, Guidi GM, Guido C, Gushwa K, Gustafson EK, Gustafson R, Hammer D, Hammond G, Hanke M, Hanks J, Hanna C, Hanson J, Harms J, Harry GM, Harry IW, Harstad ED, Hart M, Hartman MT, Haster CJ, Haughian K, Heidmann A, Heintze M, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Heptonstall AW, Heurs M, Hewitson M, Hild S, Hoak D, Hodge KA, Holt K, Hooper S, Hopkins P, Hosken DJ, Hough J, Howell EJ, Hu Y, Huerta E, Hughey B, Husa S, Huttner SH, Huynh M, Huynh-Dinh T, Ingram DR, Inta R, Isogai T, Ivanov A, Iyer BR, Izumi K, Jacobson M, James E, Jang H, Jaranowski P, Ji Y, Jiménez-Forteza F, Johnson WW, Jones DI, Jones R, Jonker RJG, Ju L, K H, Kalmus P, Kalogera V, Kandhasamy S, Kang G, Kanner JB, Karlen J, Kasprzack M, Katsavounidis E, Katzman W, Kaufer H, Kawabe K, Kawazoe F, Kéfélian F, Keiser GM, Keitel D, Kelley DB, Kells W, Khalaidovski A, Khalili FY, Khazanov EA, Kim C, Kim K, Kim N, Kim NG, Kim YM, King EJ, King PJ, Kinzel DL, Kissel JS, Klimenko S, Kline J, Koehlenbeck S, Kokeyama K, Kondrashov V, Koranda S, Korth WZ, Kowalska I, Kozak DB, Kremin A, Kringel V, Królak A, Kuehn G, Kumar A, Kumar P, Kumar R, Kuo L, Kutynia A, Kwee P, Landry M, Lantz B, Larson S, Lasky PD, Lawrie C, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lebigot EO, Lee CH, Lee HK, Lee HM, Lee J, Leonardi M, Leong JR, Le Roux A, Leroy N, Letendre N, Levin Y, Levine B, Lewis J, Li TGF, Libbrecht K, Libson A, Lin AC, Littenberg TB, Litvine V, Lockerbie NA, Lockett V, Lodhia D, Loew K, Logue J, Lombardi AL, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough J, Lubinski MJ, Lück H, Luijten E, Lundgren AP, Lynch R, Ma Y, Macarthur J, Macdonald EP, MacDonald T, Machenschalk B, MacInnis M, Macleod DM, Magana-Sandoval F, Mageswaran M, Maglione C, Mailand K, Majorana E, Maksimovic I, Malvezzi V, Man N, Manca GM, Mandel I, Mandic V, Mangano V, Mangini N, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markosyan A, Maros E, Marque J, Martelli F, Martin IW, Martin RM, Martinelli L, Martynov D, Marx JN, Mason K, Masserot A, Massinger TJ, Matichard F, Matone L, Matzner RA, Mavalvala N, Mazumder N, Mazzolo G, McCarthy R, McClelland DE, McGuire SC, McIntyre G, McIver J, McLin K, Meacher D, Meadors GD, Mehmet M, Meidam J, Meinders M, Melatos A, Mendell G, Mercer RA, Meshkov S, Messenger C, Meyers P, Miao H, Michel C, Mikhailov EE, Milano L, Milde S, Miller J, Minenkov Y, Mingarelli CMF, Mishra C, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moe B, Moesta P, Mohan M, Mohapatra SRP, Moraru D, Moreno G, Morgado N, Morriss SR, Mossavi K, Mours B, Mow-Lowry CM, Mueller CL, Mueller G, Mukherjee S, Mullavey A, Munch J, Murphy D, Murray PG, Mytidis A, Nagy MF, Kumar DN, Nardecchia I, Naticchioni L, Nayak RK, Necula V, Nelemans G, Neri I, Neri M, Newton G, Nguyen T, Nitz A, Nocera F, Nolting D, Normandin MEN, Nuttall LK, Ochsner E, O'Dell J, Oelker E, Oh JJ, Oh SH, Ohme F, Oppermann P, O'Reilly B, O'Shaughnessy R, Osthelder C, Ottaway DJ, Ottens RS, Overmier H, Owen BJ, Padilla C, Pai A, Palashov O, Palomba C, Pan H, Pan Y, Pankow C, Paoletti F, Paoletti R, Paris H, Pasqualetti A, Passaquieti R, Passuello D, Pedraza M, Penn S, Perreca A, Phelps M, Pichot M, Pickenpack M, Piergiovanni F, Pierro V, Pinard L, Pinto IM, Pitkin M, Poeld J, Poggiani R, Poteomkin A, Powell J, Prasad J, Premachandra S, Prestegard T, Price LR, Prijatelj M, Privitera S, Prodi GA, Prokhorov L, Puncken O, Punturo M, Puppo P, Qin J, Quetschke V, Quintero E, Quiroga G, Quitzow-James R, Raab FJ, Rabeling DS, Rácz I, Radkins H, Raffai P, Raja S, Rajalakshmi G, Rakhmanov M, Ramet C, Ramirez K, Rapagnani P, Raymond V, Re V, Read J, Reed CM, Regimbau T, Reid S, Reitze DH, Rhoades E, Ricci F, Riles K, Robertson NA, Robinet F, Rocchi A, Rodruck M, Rolland L, Rollins JG, Romano JD, Romano R, Romanov G, Romie JH, Rosińska D, Rowan S, Rüdiger A, Ruggi P, Ryan K, Salemi F, Sammut L, Sandberg V, Sanders JR, Sannibale V, Santiago-Prieto I, Saracco E, Sassolas B, Sathyaprakash BS, Saulson PR, Savage R, Scheuer J, Schilling R, Schnabel R, Schofield RMS, Schreiber E, Schuette D, Schutz BF, Scott J, Scott SM, Sellers D, Sengupta AS, Sentenac D, Sequino V, Sergeev A, Shaddock D, Shah S, Shahriar MS, Shaltev M, Shapiro B, Shawhan P, Shoemaker DH, Sidery TL, Siellez K, Siemens X, Sigg D, Simakov D, Singer A, Singer L, Singh R, Sintes AM, Slagmolen BJJ, Slutsky J, Smith JR, Smith M, Smith RJE, Smith-Lefebvre ND, Son EJ, Sorazu B, Souradeep T, Sperandio L, Staley A, Stebbins J, Steinlechner J, Steinlechner S, Stephens BC, Steplewski S, Stevenson S, Stone R, Stops D, Strain KA, Straniero N, Strigin S, Sturani R, Stuver AL, Summerscales TZ, Susmithan S, Sutton PJ, Swinkels B, Tacca M, Talukder D, Tanner DB, Tarabrin SP, Taylor R, Ter Braack APM, Thirugnanasambandam MP, Thomas M, Thomas P, Thorne KA, Thorne KS, Thrane E, Tiwari V, Tokmakov KV, Tomlinson C, Toncelli A, Tonelli M, Torre O, Torres CV, Torrie CI, Travasso F, Traylor G, Tse M, Ugolini D, Unnikrishnan CS, Urban AL, Urbanek K, Vahlbruch H, Vajente G, Valdes G, Vallisneri M, van den Brand JFJ, Van Den Broeck C, van der Putten S, van der Sluys MV, van Heijningen J, van Veggel AA, Vass S, Vasúth M, Vaulin R, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Verkindt D, Verma SS, Vetrano F, Viceré A, Vincent-Finley R, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Vousden WD, Vyachanin SP, Wade A, Wade L, Wade M, Walker M, Wallace L, Wang M, Wang X, Ward RL, Was M, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Welborn T, Wen L, Wessels P, West M, Westphal T, Wette K, Whelan JT, White DJ, Whiting BF, Wiesner K, Wilkinson C, Williams K, Williams L, Williams R, Williams T, Williamson AR, Willis JL, Willke B, Wimmer M, Winkler W, Wipf CC, Wiseman AG, Wittel H, Woan G, Worden J, Yablon J, Yakushin I, Yamamoto H, Yancey CC, Yang H, Yang Z, Yoshida S, Yvert M, Zadrożny A, Zanolin M, Zendri JP, Zhang F, Zhang L, Zhao C, Zhu XJ, Zucker ME, Zuraw S, Zweizig J. Improved upper limits on the stochastic gravitational-wave background from 2009-2010 LIGO and Virgo data. PHYSICAL REVIEW LETTERS 2014; 113:231101. [PMID: 25526109 DOI: 10.1103/physrevlett.113.231101] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/07/2014] [Indexed: 06/04/2023]
Abstract
Gravitational waves from a variety of sources are predicted to superpose to create a stochastic background. This background is expected to contain unique information from throughout the history of the Universe that is unavailable through standard electromagnetic observations, making its study of fundamental importance to understanding the evolution of the Universe. We carry out a search for the stochastic background with the latest data from the LIGO and Virgo detectors. Consistent with predictions from most stochastic gravitational-wave background models, the data display no evidence of a stochastic gravitational-wave signal. Assuming a gravitational-wave spectrum of Ω_{GW}(f)=Ω_{α}(f/f_{ref})^{α}, we place 95% confidence level upper limits on the energy density of the background in each of four frequency bands spanning 41.5-1726 Hz. In the frequency band of 41.5-169.25 Hz for a spectral index of α=0, we constrain the energy density of the stochastic background to be Ω_{GW}(f)<5.6×10^{-6}. For the 600-1000 Hz band, Ω_{GW}(f)<0.14(f/900 Hz)^{3}, a factor of 2.5 lower than the best previously reported upper limits. We find Ω_{GW}(f)<1.8×10^{-4} using a spectral index of zero for 170-600 Hz and Ω_{GW}(f)<1.0(f/1300 Hz)^{3} for 1000-1726 Hz, bands in which no previous direct limits have been placed. The limits in these four bands are the lowest direct measurements to date on the stochastic background. We discuss the implications of these results in light of the recent claim by the BICEP2 experiment of the possible evidence for inflationary gravitational waves.
Collapse
|
218
|
Kim N, Kim JY, Yenari MA. Pharmacological induction of the 70-kDa heat shock protein protects against brain injury. Neuroscience 2014; 284:912-919. [PMID: 25446362 DOI: 10.1016/j.neuroscience.2014.11.010] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2014] [Revised: 10/30/2014] [Accepted: 11/01/2014] [Indexed: 01/29/2023]
Abstract
The 70-kDa heat shock protein (HSP70) is known to protect the brain from injury through multiple mechanisms. We investigated the effect of pharmacological HSP70 induction in experimental traumatic brain injury (TBI). 3-month-old male C57/B6 mice were given 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) intraperitoneally (IP, 2 mg/kg) or intracerebroventricularly (ICV, 1 μg/kg) to determine whether HSP70 could be induced in the brain. Mice were subjected to TBI via cortical controlled impact, and were treated with 17-AAG (or vehicle) IP according to one of two treatment regimens: (1) 2 mg/kg at the time of injury, (2) a total of three doses (4 mg/kg) at 2 and 1d prior to TBI and again at the time of injury. Brains were assessed for HSP70 induction, hemorrhage volume at 3 d, and lesion size at 14 d post-injury. Immunohistochemistry showed that both IP and ICV administration of 17-AAG increased HSP70 expression primarily in microglia and in a few neurons by 24 h but not in astrocytes. 17-AAG induced HSP70 in injured brain tissue as early as 6 h, peaking at 48 h and largely subsiding by 72 h after IP injection. Both treatment groups showed decreased hemorrhage volume relative to untreated mice as well as improved neurobehavioral outcomes. These observations indicate that pharmacologic HSP70 induction may prove to be a promising treatment for TBI.
Collapse
|
219
|
Shon JH, Kim N, Park SJ, Oh MK, Kim EY, Lee SH, Kim YH, Shin JG. Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444). Diabetes Obes Metab 2014; 16:1028-31. [PMID: 24641348 DOI: 10.1111/dom.12292] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/12/2013] [Revised: 02/13/2014] [Accepted: 03/08/2014] [Indexed: 12/19/2022]
Abstract
This study evaluated the effects of renal impairment (RI) and haemodialysis (HD) on the pharmacokinetics of gemigliptin, a novel dipeptidyl peptidase-4 (DPP-4) inhibitor. After a 100 mg administration to subjects with normal renal function (n = 23) or RI (n = 24), plasma, urine or dialysate samples were analysed. Control subjects were matched to patients based on age, gender and body mass index. Patients with mild, moderate, severe RI and end-stage renal disease (ESRD) showed 1.20, 2.04, 1.50 and 1.66-fold (1.10, 1.49, 1.22 and 1.21-fold) increase of mean area under the time-plasma concentration curve from 0 to infinity (AUCinf) [maximum plasma concentration (Cmax)] of gemigliptin, respectively. Pharmacokinetics of gemigliptin was comparable between HD and non-HD periods in ESRD patients. Less than 4% of the dose was removed by 4 h HD. RI appeared to have modest effect on the gemigliptin disposition. No dose adjustment in patients with RI is proposed on the basis of exposure-response relationship. Impact of HD on the removal of gemigliptin was negligible.
Collapse
|
220
|
Kim H, Kim N, Cho MY, Kim NY, Kang YR, Hwang IH. Adaptation of evidence-based nursing practice guideline for central venous-port management. INT J EVID-BASED HEA 2014. [DOI: 10.1097/01.xeb.0000455178.81606.88] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
221
|
Kim T, Chang J, Kim T, Kim N, Ahn J, Koom W. The Effectiveness of Off-Protocol Upfront Chemotherapy and Preoperative Short-Course Radiation Therapy Followed by Delayed Surgery for Patients With Locally Advanced Rectal Cancer and Synchronous Metastases. Int J Radiat Oncol Biol Phys 2014. [DOI: 10.1016/j.ijrobp.2014.05.1250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
222
|
Pollick F, Kim N, Jang SH. Using intersubject correlation of fMRI data to explore similarities and differences in action representation of Classical, Romantic and Modern ballet styles. J Vis 2014. [DOI: 10.1167/14.10.1012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
223
|
Aasi J, Abbott BP, Abbott R, Abbott T, Abernathy MR, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Affeldt C, Agathos M, Aggarwal N, Aguiar OD, Ajith P, Alemic A, Allen B, Allocca A, Amariutei D, Andersen M, Anderson RA, Anderson SB, Anderson WG, Arai K, Araya MC, Arceneaux C, Areeda JS, Ast S, Aston SM, Astone P, Aufmuth P, Augustus H, Aulbert C, Aylott BE, Babak S, Baker PT, Ballardin G, Ballmer SW, Barayoga JC, Barbet M, Barish BC, Barker D, Barone F, Barr B, Barsotti L, Barsuglia M, Barton MA, Bartos I, Bassiri R, Basti A, Batch JC, Bauchrowitz J, Bauer TS, Baune C, Bavigadda V, Behnke B, Bejger M, Beker MG, Belczynski C, Bell AS, Bell C, Bergmann G, Bersanetti D, Bertolini A, Betzwieser J, Bilenko IA, Billingsley G, Birch J, Biscans S, Bitossi M, Biwer C, Bizouard MA, Black E, Blackburn JK, Blackburn L, Blair D, Bloemen S, Bock O, Bodiya TP, Boer M, Bogaert G, Bogan C, Bond C, Bondu F, Bonelli L, Bonnand R, Bork R, Born M, Boschi V, Bose S, Bosi L, Bradaschia C, Brady PR, Braginsky VB, Branchesi M, Brau JE, Briant T, Bridges DO, Brillet A, Brinkmann M, Brisson V, Brooks AF, Brown DA, Brown DD, Brückner F, Buchman S, Buikema A, Bulik T, Bulten HJ, Buonanno A, Burman R, Buskulic D, Buy C, Cadonati L, Cagnoli G, Calderón Bustillo J, Calloni E, Camp JB, Campsie P, Cannon KC, Canuel B, Cao J, Capano CD, Carbognani F, Carbone L, Caride S, Castaldi G, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Celerier C, Cella G, Cepeda C, Cesarini E, Chakraborty R, Chalermsongsak T, Chamberlin SJ, Chao S, Charlton P, Chassande-Mottin E, Chen X, Chen Y, Chincarini A, Chiummo A, Cho HS, Cho M, Chow JH, Christensen N, Chu Q, Chua SSY, Chung S, Ciani G, Clara F, Clark DE, Clark JA, Clayton JH, Cleva F, Coccia E, Cohadon PF, Colla A, Collette C, Colombini M, Cominsky L, Constancio M, Conte A, Cook D, Corbitt TR, Cornish N, Corsi A, Costa CA, Coughlin MW, Coulon JP, Countryman S, Couvares P, Coward DM, Cowart MJ, Coyne DC, Coyne R, Craig K, Creighton JDE, Croce RP, Crowder SG, Cumming A, Cunningham L, Cuoco E, Cutler C, Dahl K, Dal Canton T, Damjanic M, Danilishin SL, D'Antonio S, Danzmann K, Dattilo V, Daveloza H, Davier M, Davies GS, Daw EJ, Day R, Dayanga T, DeBra D, Debreczeni G, Degallaix J, Deléglise S, Del Pozzo W, Denker T, Dent T, Dereli H, Dergachev V, De Rosa R, DeRosa RT, DeSalvo R, Dhurandhar S, Díaz M, Dickson J, Di Fiore L, Di Lieto A, Di Palma I, Di Virgilio A, Dolique V, Dominguez E, Donovan F, Dooley KL, Doravari S, Douglas R, Downes TP, Drago M, Drever RWP, Driggers JC, Du Z, Ducrot M, Dwyer S, Eberle T, Edo T, Edwards M, Effler A, Eggenstein HB, Ehrens P, Eichholz J, Eikenberry SS, Endrőczi G, Essick R, Etzel T, Evans M, Evans T, Factourovich M, Fafone V, Fairhurst S, Fan X, Fang Q, Farinon S, Farr B, Farr WM, Favata M, Fazi D, Fehrmann H, Fejer MM, Feldbaum D, Feroz F, Ferrante I, Ferreira EC, Ferrini F, Fidecaro F, Finn LS, Fiori I, Fisher RP, Flaminio R, Fournier JD, Franco S, Frasca S, Frasconi F, Frede M, Frei Z, Freise A, Frey R, Fricke TT, Fritschel P, Frolov VV, Fulda P, Fyffe M, Gair JR, Gammaitoni L, Gaonkar S, Garufi F, Gehrels N, Gemme G, Gendre B, Genin E, Gennai A, Ghosh S, Giaime JA, Giardina KD, Giazotto A, Gleason J, Goetz E, Goetz R, Gondan L, González G, Gordon N, Gorodetsky ML, Gossan S, Goßler S, Gouaty R, Gräf C, Graff PB, Granata M, Grant A, Gras S, Gray C, Greenhalgh RJS, Gretarsson AM, Groot P, Grote H, Grover K, Grunewald S, Guidi GM, Guido CJ, Gushwa K, Gustafson EK, Gustafson R, Ha J, Hall ED, Hamilton W, Hammer D, Hammond G, Hanke M, Hanks J, Hanna C, Hannam MD, Hanson J, Harms J, Harry GM, Harry IW, Harstad ED, Hart M, Hartman MT, Haster CJ, Haughian K, Heidmann A, Heintze M, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Heptonstall AW, Heurs M, Hewitson M, Hild S, Hoak D, Hodge KA, Hofman D, Holt K, Hopkins P, Horrom T, Hoske D, Hosken DJ, Hough J, Howell EJ, Hu Y, Huerta E, Hughey B, Husa S, Huttner SH, Huynh M, Huynh-Dinh T, Idrisy A, Ingram DR, Inta R, Islas G, Isogai T, Ivanov A, Iyer BR, Izumi K, Jacobson M, Jang H, Jaranowski P, Ji Y, Jiménez-Forteza F, Johnson WW, Jones DI, Jones R, Jonker RJG, Ju L, Haris K, Kalmus P, Kalogera V, Kandhasamy S, Kang G, Kanner JB, Karlen J, Kasprzack M, Katsavounidis E, Katzman W, Kaufer H, Kaufer S, Kaur T, Kawabe K, Kawazoe F, Kéfélian F, Keiser GM, Keitel D, Kelley DB, Kells W, Keppel DG, Khalaidovski A, Khalili FY, Khazanov EA, Kim C, Kim K, Kim NG, Kim N, Kim S, Kim YM, King EJ, King PJ, Kinzel DL, Kissel JS, Klimenko S, Kline J, Koehlenbeck S, Kokeyama K, Kondrashov V, Koranda S, Korth WZ, Kowalska I, Kozak DB, Kringel V, Krishnan B, Królak A, Kuehn G, Kumar A, Kumar DN, Kumar P, Kumar R, Kuo L, Kutynia A, Lam PK, Landry M, Lantz B, Larson S, Lasky PD, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lebigot EO, Lee CH, Lee HK, Lee HM, Lee J, Lee PJ, Leonardi M, Leong JR, Leonor I, Le Roux A, Leroy N, Letendre N, Levin Y, Levine B, Lewis J, Li TGF, Libbrecht K, Libson A, Lin AC, Littenberg TB, Lockerbie NA, Lockett V, Lodhia D, Loew K, Logue J, Lombardi AL, Lopez E, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough J, Lubinski MJ, Lück H, Lundgren AP, Ma Y, Macdonald EP, MacDonald T, Machenschalk B, MacInnis M, Macleod DM, Magaña-Sandoval F, Magee R, Mageswaran M, Maglione C, Mailand K, Majorana E, Maksimovic I, Malvezzi V, Man N, Manca GM, Mandel I, Mandic V, Mangano V, Mangini NM, Mansell G, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markosyan A, Maros E, Marque J, Martelli F, Martin IW, Martin RM, Martinelli L, Martynov D, Marx JN, Mason K, Masserot A, Massinger TJ, Matichard F, Matone L, Mavalvala N, May G, Mazumder N, Mazzolo G, McCarthy R, McClelland DE, McGuire SC, McIntyre G, McIver J, McLin K, Meacher D, Meadors GD, Mehmet M, Meidam J, Meinders M, Melatos A, Mendell G, Mercer RA, Meshkov S, Messenger C, Meyer MS, Meyers PM, Mezzani F, Miao H, Michel C, Mikhailov EE, Milano L, Miller J, Minenkov Y, Mingarelli CMF, Mishra C, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moe B, Moggi A, Mohan M, Mohapatra SRP, Moraru D, Moreno G, Morgado N, Morriss SR, Mossavi K, Mours B, Mow-Lowry CM, Mueller CL, Mueller G, Mukherjee S, Mullavey A, Munch J, Murphy D, Murray PG, Mytidis A, Nagy MF, Nardecchia I, Naticchioni L, Nayak RK, Necula V, Nelemans G, Neri I, Neri M, Newton G, Nguyen T, Nielsen AB, Nissanke S, Nitz AH, Nocera F, Nolting D, Normandin MEN, Nuttall LK, Ochsner E, O'Dell J, Oelker E, Oh JJ, Oh SH, Ohme F, Omar S, Oppermann P, Oram R, O'Reilly B, Ortega W, O'Shaughnessy R, Osthelder C, Ottaway DJ, Ottens RS, Overmier H, Owen BJ, Padilla C, Pai A, Palashov O, Palomba C, Pan H, Pan Y, Pankow C, Paoletti F, Papa MA, Paris H, Pasqualetti A, Passaquieti R, Passuello D, Pedraza M, Pele A, Penn S, Perreca A, Phelps M, Pichot M, Pickenpack M, Piergiovanni F, Pierro V, Pinard L, Pinto IM, Pitkin M, Poeld J, Poggiani R, Poteomkin A, Powell J, Prasad J, Predoi V, Premachandra S, Prestegard T, Price LR, Prijatelj M, Privitera S, Prodi GA, Prokhorov L, Puncken O, Punturo M, Puppo P, Pürrer M, Qin J, Quetschke V, Quintero E, Quitzow-James R, Raab FJ, Rabeling DS, Rácz I, Radkins H, Raffai P, Raja S, Rajalakshmi G, Rakhmanov M, Ramet C, Ramirez K, Rapagnani P, Raymond V, Razzano M, Re V, Recchia S, Reed CM, Regimbau T, Reid S, Reitze DH, Reula O, Rhoades E, Ricci F, Riesen R, Riles K, Robertson NA, Robinet F, Rocchi A, Roddy SB, Rolland L, Rollins JG, Romano R, Romanov G, Romie JH, Rosińska D, Rowan S, Rüdiger A, Ruggi P, Ryan K, Salemi F, Sammut L, Sandberg V, Sanders JR, Sankar S, Sannibale V, Santiago-Prieto I, Saracco E, Sassolas B, Sathyaprakash BS, Saulson PR, Savage R, Scheuer J, Schilling R, Schilman M, Schmidt P, Schnabel R, Schofield RMS, Schreiber E, Schuette D, Schutz BF, Scott J, Scott SM, Sellers D, Sengupta AS, Sentenac D, Sequino V, Sergeev A, Shaddock DA, Shah S, Shahriar MS, Shaltev M, Shao Z, Shapiro B, Shawhan P, Shoemaker DH, Sidery TL, Siellez K, Siemens X, Sigg D, Simakov D, Singer A, Singer L, Singh R, Sintes AM, Slagmolen BJJ, Slutsky J, Smith JR, Smith MR, Smith RJE, Smith-Lefebvre ND, Son EJ, Sorazu B, Souradeep T, Staley A, Stebbins J, Steinke M, Steinlechner J, Steinlechner S, Stephens BC, Steplewski S, Stevenson S, Stone R, Stops D, Strain KA, Straniero N, Strigin S, Sturani R, Stuver AL, Summerscales TZ, Susmithan S, Sutton PJ, Swinkels B, Tacca M, Talukder D, Tanner DB, Tao J, Tarabrin SP, Taylor R, Tellez G, Thirugnanasambandam MP, Thomas M, Thomas P, Thorne KA, Thorne KS, Thrane E, Tiwari V, Tokmakov KV, Tomlinson C, Tonelli M, Torres CV, Torrie CI, Travasso F, Traylor G, Tse M, Tshilumba D, Tuennermann H, Ugolini D, Unnikrishnan CS, Urban AL, Usman SA, Vahlbruch H, Vajente G, Valdes G, Vallisneri M, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, van der Sluys MV, van Heijningen J, van Veggel AA, Vass S, Vasúth M, Vaulin R, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Verkindt D, Vetrano F, Viceré A, Vincent-Finley R, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Vousden WD, Vyachanin SP, Wade AR, Wade L, Wade M, Walker M, Wallace L, Walsh S, Wang M, Wang X, Ward RL, Was M, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Welborn T, Wen L, Wessels P, West M, Westphal T, Wette K, Whelan JT, White DJ, Whiting BF, Wiesner K, Wilkinson C, Williams K, Williams L, Williams R, Williams TD, Williamson AR, Willis JL, Willke B, Wimmer M, Winkler W, Wipf CC, Wiseman AG, Wittel H, Woan G, Wolovick N, Worden J, Wu Y, Yablon J, Yakushin I, Yam W, Yamamoto H, Yancey CC, Yang H, Yoshida S, Yvert M, Zadrożny A, Zanolin M, Zendri JP, Zhang F, Zhang L, Zhao C, Zhu H, Zhu XJ, Zucker ME, Zuraw S, Zweizig J, Aptekar RL, Atteia JL, Cline T, Connaughton V, Frederiks DD, Golenetskii SV, Hurley K, Krimm HA, Marisaldi M, Pal'shin VD, Palmer D, Svinkin DS, Terada Y, von Kienlin A. Search for gravitational waves associated with γ-ray bursts detected by the interplanetary network. PHYSICAL REVIEW LETTERS 2014; 113:011102. [PMID: 25032916 DOI: 10.1103/physrevlett.113.011102] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/07/2014] [Indexed: 05/21/2023]
Abstract
We present the results of a search for gravitational waves associated with 223 γ-ray bursts (GRBs) detected by the InterPlanetary Network (IPN) in 2005-2010 during LIGO's fifth and sixth science runs and Virgo's first, second, and third science runs. The IPN satellites provide accurate times of the bursts and sky localizations that vary significantly from degree scale to hundreds of square degrees. We search for both a well-modeled binary coalescence signal, the favored progenitor model for short GRBs, and for generic, unmodeled gravitational wave bursts. Both searches use the event time and sky localization to improve the gravitational wave search sensitivity as compared to corresponding all-time, all-sky searches. We find no evidence of a gravitational wave signal associated with any of the IPN GRBs in the sample, nor do we find evidence for a population of weak gravitational wave signals associated with the GRBs. For all IPN-detected GRBs, for which a sufficient duration of quality gravitational wave data are available, we place lower bounds on the distance to the source in accordance with an optimistic assumption of gravitational wave emission energy of 10(-2)M⊙c(2) at 150 Hz, and find a median of 13 Mpc. For the 27 short-hard GRBs we place 90% confidence exclusion distances to two source models: a binary neutron star coalescence, with a median distance of 12 Mpc, or the coalescence of a neutron star and black hole, with a median distance of 22 Mpc. Finally, we combine this search with previously published results to provide a population statement for GRB searches in first-generation LIGO and Virgo gravitational wave detectors and a resulting examination of prospects for the advanced gravitational wave detectors.
Collapse
|
224
|
Aasi J, Abbott BP, Abbott R, Abbott T, Abernathy MR, Acernese F, Ackley K, Adams C, Adams T, Addesso P, Adhikari RX, Affeldt C, Agathos M, Aggarwal N, Aguiar OD, Ajith P, Alemic A, Allen B, Allocca A, Amariutei D, Andersen M, Anderson RA, Anderson SB, Anderson WG, Arai K, Araya MC, Arceneaux C, Areeda JS, Ast S, Aston SM, Astone P, Aufmuth P, Augustus H, Aulbert C, Aylott BE, Babak S, Baker PT, Ballardin G, Ballmer SW, Barayoga JC, Barbet M, Barish BC, Barker D, Barone F, Barr B, Barsotti L, Barsuglia M, Barton MA, Bartos I, Bassiri R, Basti A, Batch JC, Bauchrowitz J, Bauer TS, Baune C, Bavigadda V, Behnke B, Bejger M, Beker MG, Belczynski C, Bell AS, Bell C, Bergmann G, Bersanetti D, Bertolini A, Betzwieser J, Bilenko IA, Billingsley G, Birch J, Biscans S, Bitossi M, Biwer C, Bizouard MA, Black E, Blackburn JK, Blackburn L, Blair D, Bloemen S, Bock O, Bodiya TP, Boer M, Bogaert G, Bogan C, Bond C, Bondu F, Bonelli L, Bonnand R, Bork R, Born M, Boschi V, Bose S, Bosi L, Bradaschia C, Brady PR, Braginsky VB, Branchesi M, Brau JE, Briant T, Bridges DO, Brillet A, Brinkmann M, Brisson V, Brooks AF, Brown DA, Brown DD, Brückner F, Buchman S, Buikema A, Bulik T, Bulten HJ, Buonanno A, Burman R, Buskulic D, Buy C, Cadonati L, Cagnoli G, Calderón Bustillo J, Calloni E, Camp JB, Campsie P, Cannon KC, Canuel B, Cao J, Capano CD, Carbognani F, Carbone L, Caride S, Castaldi G, Caudill S, Cavaglià M, Cavalier F, Cavalieri R, Celerier C, Cella G, Cepeda C, Cesarini E, Chakraborty R, Chalermsongsak T, Chamberlin SJ, Chao S, Charlton P, Chassande-Mottin E, Chen X, Chen Y, Chincarini A, Chiummo A, Cho HS, Cho M, Chow JH, Christensen N, Chu Q, Chua SSY, Chung S, Ciani G, Clara F, Clark DE, Clark JA, Clayton JH, Cleva F, Coccia E, Cohadon PF, Colla A, Collette C, Colombini M, Cominsky L, Constancio M, Conte A, Cook D, Corbitt TR, Cornish N, Corsi A, Costa CA, Coughlin MW, Coulon JP, Countryman S, Couvares P, Coward DM, Cowart MJ, Coyne DC, Coyne R, Craig K, Creighton JDE, Croce RP, Crowder SG, Cumming A, Cunningham L, Cuoco E, Cutler C, Dahl K, Dal Canton T, Damjanic M, Danilishin SL, D'Antonio S, Danzmann K, Dattilo V, Daveloza H, Davier M, Davies GS, Daw EJ, Day R, Dayanga T, DeBra D, Debreczeni G, Degallaix J, Deléglise S, Del Pozzo W, Denker T, Dent T, Dereli H, Dergachev V, De Rosa R, DeRosa RT, DeSalvo R, Dhurandhar S, Díaz M, Dickson J, Di Fiore L, Di Lieto A, Di Palma I, Di Virgilio A, Dolique V, Dominguez E, Donovan F, Dooley KL, Doravari S, Douglas R, Downes TP, Drago M, Drever RWP, Driggers JC, Du Z, Ducrot M, Dwyer S, Eberle T, Edo T, Edwards M, Effler A, Eggenstein HB, Ehrens P, Eichholz J, Eikenberry SS, Endrőczi G, Essick R, Etzel T, Evans M, Evans T, Factourovich M, Fafone V, Fairhurst S, Fan X, Fang Q, Farinon S, Farr B, Farr WM, Favata M, Fazi D, Fehrmann H, Fejer MM, Feldbaum D, Feroz F, Ferrante I, Ferreira EC, Ferrini F, Fidecaro F, Finn LS, Fiori I, Fisher RP, Flaminio R, Fournier JD, Franco S, Frasca S, Frasconi F, Frede M, Frei Z, Freise A, Frey R, Fricke TT, Fritschel P, Frolov VV, Fulda P, Fyffe M, Gair JR, Gammaitoni L, Gaonkar S, Garufi F, Gehrels N, Gemme G, Gendre B, Genin E, Gennai A, Ghosh S, Giaime JA, Giardina KD, Giazotto A, Gleason J, Goetz E, Goetz R, Gondan L, González G, Gordon N, Gorodetsky ML, Gossan S, Goßler S, Gouaty R, Gräf C, Graff PB, Granata M, Grant A, Gras S, Gray C, Greenhalgh RJS, Gretarsson AM, Groot P, Grote H, Grover K, Grunewald S, Guidi GM, Guido CJ, Gushwa K, Gustafson EK, Gustafson R, Ha J, Hall ED, Hamilton W, Hammer D, Hammond G, Hanke M, Hanks J, Hanna C, Hannam MD, Hanson J, Harms J, Harry GM, Harry IW, Harstad ED, Hart M, Hartman MT, Haster CJ, Haughian K, Heidmann A, Heintze M, Heitmann H, Hello P, Hemming G, Hendry M, Heng IS, Heptonstall AW, Heurs M, Hewitson M, Hild S, Hoak D, Hodge KA, Hofman D, Holt K, Hopkins P, Horrom T, Hoske D, Hosken DJ, Hough J, Howell EJ, Hu Y, Huerta E, Hughey B, Husa S, Huttner SH, Huynh M, Huynh-Dinh T, Idrisy A, Ingram DR, Inta R, Islas G, Isogai T, Ivanov A, Iyer BR, Izumi K, Jacobson M, Jang H, Jaranowski P, Ji Y, Jiménez-Forteza F, Johnson WW, Jones DI, Jones R, Jonker RJG, Ju L, Haris K, Kalmus P, Kalogera V, Kandhasamy S, Kang G, Kanner JB, Karlen J, Kasprzack M, Katsavounidis E, Katzman W, Kaufer H, Kaufer S, Kaur T, Kawabe K, Kawazoe F, Kéfélian F, Keiser GM, Keitel D, Kelley DB, Kells W, Keppel DG, Khalaidovski A, Khalili FY, Khazanov EA, Kim C, Kim K, Kim NG, Kim N, Kim S, Kim YM, King EJ, King PJ, Kinzel DL, Kissel JS, Klimenko S, Kline J, Koehlenbeck S, Kokeyama K, Kondrashov V, Koranda S, Korth WZ, Kowalska I, Kozak DB, Kringel V, Krishnan B, Królak A, Kuehn G, Kumar A, Kumar DN, Kumar P, Kumar R, Kuo L, Kutynia A, Lam PK, Landry M, Lantz B, Larson S, Lasky PD, Lazzarini A, Lazzaro C, Leaci P, Leavey S, Lebigot EO, Lee CH, Lee HK, Lee HM, Lee J, Lee PJ, Leonardi M, Leong JR, Leonor I, Le Roux A, Leroy N, Letendre N, Levin Y, Levine B, Lewis J, Li TGF, Libbrecht K, Libson A, Lin AC, Littenberg TB, Lockerbie NA, Lockett V, Lodhia D, Loew K, Logue J, Lombardi AL, Lopez E, Lorenzini M, Loriette V, Lormand M, Losurdo G, Lough J, Lubinski MJ, Lück H, Lundgren AP, Ma Y, Macdonald EP, MacDonald T, Machenschalk B, MacInnis M, Macleod DM, Magaña-Sandoval F, Magee R, Mageswaran M, Maglione C, Mailand K, Majorana E, Maksimovic I, Malvezzi V, Man N, Manca GM, Mandel I, Mandic V, Mangano V, Mangini NM, Mansell G, Mantovani M, Marchesoni F, Marion F, Márka S, Márka Z, Markosyan A, Maros E, Marque J, Martelli F, Martin IW, Martin RM, Martinelli L, Martynov D, Marx JN, Mason K, Masserot A, Massinger TJ, Matichard F, Matone L, Mavalvala N, May G, Mazumder N, Mazzolo G, McCarthy R, McClelland DE, McGuire SC, McIntyre G, McIver J, McLin K, Meacher D, Meadors GD, Mehmet M, Meidam J, Meinders M, Melatos A, Mendell G, Mercer RA, Meshkov S, Messenger C, Meyer MS, Meyers PM, Mezzani F, Miao H, Michel C, Mikhailov EE, Milano L, Miller J, Minenkov Y, Mingarelli CMF, Mishra C, Mitra S, Mitrofanov VP, Mitselmakher G, Mittleman R, Moe B, Moggi A, Mohan M, Mohapatra SRP, Moraru D, Moreno G, Morgado N, Morriss SR, Mossavi K, Mours B, Mow-Lowry CM, Mueller CL, Mueller G, Mukherjee S, Mullavey A, Munch J, Murphy D, Murray PG, Mytidis A, Nagy MF, Nardecchia I, Naticchioni L, Nayak RK, Necula V, Nelemans G, Neri I, Neri M, Newton G, Nguyen T, Nielsen AB, Nissanke S, Nitz AH, Nocera F, Nolting D, Normandin MEN, Nuttall LK, Ochsner E, O'Dell J, Oelker E, Oh JJ, Oh SH, Ohme F, Omar S, Oppermann P, Oram R, O'Reilly B, Ortega W, O'Shaughnessy R, Osthelder C, Ottaway DJ, Ottens RS, Overmier H, Owen BJ, Padilla C, Pai A, Palashov O, Palomba C, Pan H, Pan Y, Pankow C, Paoletti F, Papa MA, Paris H, Pasqualetti A, Passaquieti R, Passuello D, Pedraza M, Pele A, Penn S, Perreca A, Phelps M, Pichot M, Pickenpack M, Piergiovanni F, Pierro V, Pinard L, Pinto IM, Pitkin M, Poeld J, Poggiani R, Poteomkin A, Powell J, Prasad J, Predoi V, Premachandra S, Prestegard T, Price LR, Prijatelj M, Privitera S, Prodi GA, Prokhorov L, Puncken O, Punturo M, Puppo P, Pürrer M, Qin J, Quetschke V, Quintero E, Quitzow-James R, Raab FJ, Rabeling DS, Rácz I, Radkins H, Raffai P, Raja S, Rajalakshmi G, Rakhmanov M, Ramet C, Ramirez K, Rapagnani P, Raymond V, Razzano M, Re V, Recchia S, Reed CM, Regimbau T, Reid S, Reitze DH, Reula O, Rhoades E, Ricci F, Riesen R, Riles K, Robertson NA, Robinet F, Rocchi A, Roddy SB, Rolland L, Rollins JG, Romano R, Romanov G, Romie JH, Rosińska D, Rowan S, Rüdiger A, Ruggi P, Ryan K, Salemi F, Sammut L, Sandberg V, Sanders JR, Sankar S, Sannibale V, Santiago-Prieto I, Saracco E, Sassolas B, Sathyaprakash BS, Saulson PR, Savage R, Scheuer J, Schilling R, Schilman M, Schmidt P, Schnabel R, Schofield RMS, Schreiber E, Schuette D, Schutz BF, Scott J, Scott SM, Sellers D, Sengupta AS, Sentenac D, Sequino V, Sergeev A, Shaddock DA, Shah S, Shahriar MS, Shaltev M, Shao Z, Shapiro B, Shawhan P, Shoemaker DH, Sidery TL, Siellez K, Siemens X, Sigg D, Simakov D, Singer A, Singer L, Singh R, Sintes AM, Slagmolen BJJ, Slutsky J, Smith JR, Smith MR, Smith RJE, Smith-Lefebvre ND, Son EJ, Sorazu B, Souradeep T, Staley A, Stebbins J, Steinke M, Steinlechner J, Steinlechner S, Stephens BC, Steplewski S, Stevenson S, Stone R, Stops D, Strain KA, Straniero N, Strigin S, Sturani R, Stuver AL, Summerscales TZ, Susmithan S, Sutton PJ, Swinkels B, Tacca M, Talukder D, Tanner DB, Tao J, Tarabrin SP, Taylor R, Tellez G, Thirugnanasambandam MP, Thomas M, Thomas P, Thorne KA, Thorne KS, Thrane E, Tiwari V, Tokmakov KV, Tomlinson C, Tonelli M, Torres CV, Torrie CI, Travasso F, Traylor G, Tse M, Tshilumba D, Tuennermann H, Ugolini D, Unnikrishnan CS, Urban AL, Usman SA, Vahlbruch H, Vajente G, Valdes G, Vallisneri M, van Beuzekom M, van den Brand JFJ, Van Den Broeck C, van der Sluys MV, van Heijningen J, van Veggel AA, Vass S, Vasúth M, Vaulin R, Vecchio A, Vedovato G, Veitch J, Veitch PJ, Venkateswara K, Verkindt D, Vetrano F, Viceré A, Vincent-Finley R, Vinet JY, Vitale S, Vo T, Vocca H, Vorvick C, Vousden WD, Vyachanin SP, Wade AR, Wade L, Wade M, Walker M, Wallace L, Walsh S, Wang M, Wang X, Ward RL, Was M, Weaver B, Wei LW, Weinert M, Weinstein AJ, Weiss R, Welborn T, Wen L, Wessels P, West M, Westphal T, Wette K, Whelan JT, White DJ, Whiting BF, Wiesner K, Wilkinson C, Williams K, Williams L, Williams R, Williams TD, Williamson AR, Willis JL, Willke B, Wimmer M, Winkler W, Wipf CC, Wiseman AG, Wittel H, Woan G, Wolovick N, Worden J, Wu Y, Yablon J, Yakushin I, Yam W, Yamamoto H, Yancey CC, Yang H, Yoshida S, Yvert M, Zadrożny A, Zanolin M, Zendri JP, Zhang F, Zhang L, Zhao C, Zhu H, Zhu XJ, Zucker ME, Zuraw S, Zweizig J, Aptekar RL, Atteia JL, Cline T, Connaughton V, Frederiks DD, Golenetskii SV, Hurley K, Krimm HA, Marisaldi M, Pal'shin VD, Palmer D, Svinkin DS, Terada Y, von Kienlin A. Search for gravitational waves associated with γ-ray bursts detected by the interplanetary network. PHYSICAL REVIEW LETTERS 2014; 113:011102. [PMID: 25032916 DOI: 10.1103/physrevd.89.122004] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/07/2014] [Indexed: 05/21/2023]
Abstract
We present the results of a search for gravitational waves associated with 223 γ-ray bursts (GRBs) detected by the InterPlanetary Network (IPN) in 2005-2010 during LIGO's fifth and sixth science runs and Virgo's first, second, and third science runs. The IPN satellites provide accurate times of the bursts and sky localizations that vary significantly from degree scale to hundreds of square degrees. We search for both a well-modeled binary coalescence signal, the favored progenitor model for short GRBs, and for generic, unmodeled gravitational wave bursts. Both searches use the event time and sky localization to improve the gravitational wave search sensitivity as compared to corresponding all-time, all-sky searches. We find no evidence of a gravitational wave signal associated with any of the IPN GRBs in the sample, nor do we find evidence for a population of weak gravitational wave signals associated with the GRBs. For all IPN-detected GRBs, for which a sufficient duration of quality gravitational wave data are available, we place lower bounds on the distance to the source in accordance with an optimistic assumption of gravitational wave emission energy of 10(-2)M⊙c(2) at 150 Hz, and find a median of 13 Mpc. For the 27 short-hard GRBs we place 90% confidence exclusion distances to two source models: a binary neutron star coalescence, with a median distance of 12 Mpc, or the coalescence of a neutron star and black hole, with a median distance of 22 Mpc. Finally, we combine this search with previously published results to provide a population statement for GRB searches in first-generation LIGO and Virgo gravitational wave detectors and a resulting examination of prospects for the advanced gravitational wave detectors.
Collapse
|
225
|
Yu M, Shin YJ, Kim N, Yoo G, Park S, Kim SH. Determination of Saponins and Flavonoids in Ivy Leaf Extracts Using HPLC-DAD. J Chromatogr Sci 2014; 53:478-83. [DOI: 10.1093/chromsci/bmu068] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|